Shared on 01 May 25
Fair value Increased 23%EMA Approval And Global Launch Will Expand Oncology Markets
Shared on 23 Apr 25
Fair value Decreased 15%ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget has decreased revenue growth from 36.0% to 30.4% and increased future PE multiple from 7.6x to 9.1x.
Shared on 17 Apr 25
Fair value Increased 18%ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Shared on 09 Apr 25
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 0.59%ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 6.24%ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 13 Mar 25
Fair value Decreased 20%ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
AnalystConsensusTarget has decreased revenue growth from 43.9% to 36.0%.